Novartis China President Zhang Ying Named to Fortune China's Most Influential Businesswomen List 2023

The list of "China's Most Influential Women in Business" by Fortune (Chinese Edition) was initiated in 2010. The list includes two parts: the list of China's Most Influential Women in Business, and the Future List of China's Most Influential Women in Business. The former consists of the most outstanding women across various industries, including female leaders of large enterprises; the latter highlights China's emerging female leaders, including entrepreneurs, professional managers, rising stars in industries, and opinion leaders.

As President of Novartis China, Ms. Zhang Ying is responsible for driving the implementation of Novartis China’s integrated strategy, formulating strategies and managing operations in mainland China and Hong Kong, and enhancing mutual trust between Novartis and society. Since joining Novartis in 2011, Ms. Zhang has held several senior management positions, including President of Novartis Pharmaceuticals China and President of Novartis Innovative Drugs China, and also served as President and head of operations at Novartis Poland.

Under her leadership, Novartis China has maintained steady growth while actively fulfilling its corporate mission, continuously accelerating the introduction of innovative drugs with high clinical value into China, and vigorously improving the accessibility of medicines.

Currently, Novartis has received approval for approximately 100 innovative drugs and indications in China. In recent years, the pace of launching Novartis' innovative drugs in China has been continuously accelerating, creating several "firsts" or "only ones" in China across various therapeutic fields including cardiovascular, dermatology immunology, oncology, and central nervous system.

Since 2017, Novartis has had more than 30 innovative drugs included in the national medical insurance catalog.

Novartis also leverages China's "Pilot Program" and other policies to introduce multiple innovative overseas drugs to Boao Lecheng and the Guangdong-Hong Kong-Macao Greater Bay Area, enabling Chinese patients in urgent need to access advanced medicines and treatment options in sync with international standards.

Novartis China continues to deepen its cooperation with medical institutions, academic associations, and technology companies in China, jointly building a healthcare ecosystem.

Multiple standardized treatment centers covering cardiovascular diseases, psoriasis, and eye diseases have been jointly established in China. They are actively exploring the application of digital and artificial intelligence technologies in the healthcare industry and have developed a home-based disease management platform for patients.

Novartis focuses on innovative drugs, targeting disease areas with urgent needs for Chinese patients. It continuously accelerates the introduction of these drugs and therapies into China to benefit Chinese patients. A diverse and inclusive corporate culture is the cornerstone of achieving all this. This honor is not only a recognition of me personally, but also an acknowledgment of Novartis' unique corporate culture of 'inspiring, seeking knowledge, and empowering.'

In recent years, Novartis has continuously promoted a corporate culture transformation centered on "inspiring, seeking knowledge, and empowering." Guided by this corporate culture, Novartis stimulates employees' internal drive and sense of mission. On an innovative, diverse, and open platform, employees constantly achieve self-breakthroughs while enhancing organizational capabilities and compliant operations, providing strong momentum for the realization of the company's mission and rapid business growth.

At Novartis China, Ms. Zhang Ying actively advocates for a diverse and inclusive work environment, helping to enhance women's leadership. Currently, the proportion of female employees and female management at Novartis China exceeds half.

Editor: Bai Ji

Disclaimer: This article is a reprint from PharmNet. The images and text are the property of the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding content, copyright, or other problems, please leave a message on this platform, and we will address it promptly.